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Anna Da Roit, MD,a and Claudio Baracchini, MD,b Padova, Italy
Objective: Carotid endarterectomy (CEA) remains the gold standard for treating carotid disease in selected symptomatic
and asymptomatic patients, though carotid angioplasty and stenting has emerged as a safe alternative. The aim of this
study was to assess the durability of CEA in a large series of patients followed up according to a strict clinical and ul-
trasonographic protocol.
Methods: Over a 23-year period (1990-2012) a total of 1773 patients (1251 men and 522 women) with a mean age of
75.2 years (range, 31 to 96 years) who underwent 2007 consecutive primary eversion CEAs performed by the same
surgeon under general anesthesia with electroencephalographic monitoring and selective shunting were prospectively
followed up with ultrasonography at 1, 6, and 12 months, then yearly. A long-term follow-up (median, 11.2 years; mean,
12.9 years) was obtained for 1680 patients (94.8%). End points were perioperative (30-day) stroke and death and late
carotid restenosis/occlusion rates.
Results:More than two in three of the lesions (1446 of 2007, 72.1%) were symptomatic at the time of surgery, with a 25%
rate of preoperative stroke. Preoperative antiplatelet or anticoagulant therapy was used by 1675 patients (94.4%), whereas
918 (51.8%) were receiving statin treatment. Overall, there were eight (0.4%) perioperative strokes and no deaths. During
the follow-up, there were nine (0.47%) asymptomatic late carotid restenoses (six moderate [50%-69%] and three severe
[$70%]) and one (0.05%) carotid occlusion. Nine patients (0.47%) had late ipsilateral strokes, none of them related to
restenosis/occlusion. Overall, there were 159 late deaths (9.4%).
Conclusions: The results of this study show that eversion CEA can be performed in symptomatic and asymptomatic
patients with an extremely low perioperative stroke/death risk and a negligible incidence of late restenosis/occlusion,
thus assuring a persistently good protection against the risk of cerebral ischemia. (J Vasc Surg 2014;59:1274-81.)Randomized controlled trials (RCTs)1-4 have
validated the efﬁcacy of carotid endarterectomy (CEA)
for stroke prevention in selected patients with symptom-
atic internal carotid artery stenosis and, to a lesser extent,
in cases of asymptomatic carotid disease, with acceptably
low perioperative (30-day) stroke and death risks.5 Large
RCTs have also recently addressed the question of the
relative safety of carotid artery stenting (CAS) vs CEA
in symptomatic and asymptomatic patients,6,7 and CAS
has emerged as a good alternative to surgery in selected
patients. CEA nonetheless remains the ﬁrst choice for
revascularization treatment for symptomatic and asymp-
tomatic carotid lesions at most centers.8 A >50% reste-
nosis rate at the surgical site, detected by ultrasound
according to the North American Symptomatic Carotid
Endarterectomy Trial (NASCET) criteria,9 represents a
noteworthy drawback of CEA, however, which can limit
the long-term beneﬁt of revascularization for the purpose
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4CEA restenosis differs considerably, and a review of the
literature discloses a variability relating to the length of
follow-up, the criteria for deﬁning restenosis, and the
method used to close the arteriotomy, which appears
to strongly inﬂuence recurrence. The risk of restenosis
is reportedly highest in the ﬁrst 2 to 3 years after CEA
(10% in the ﬁrst year, 3% in the second, and 2% in the
third),10 and it is attributable to intimal hyperplasia,
whereas any later development of restenosis (>5 years)
is consistent with progression of the underlying athero-
sclerotic disease,10 so it is not different from the primary
carotid lesion.11 The purported tendency of restenosis to
cause stroke also appears to be highly variable. The rela-
tive risk of stroke reported in patients with restenosis as
compared with those without restenosis ranges from 0.1
to 10, with a mean of 1.88, but it is generally lower than
the stroke rate associated with a primary lesion.10
Despite the reportedly low though not insigniﬁcant inci-
dence of restenosis after CEA, redo surgery is infrequent
and is related mainly to symptomatic severe restenosis or
lesions rapidly progressing toward occlusion.12,13
The present observational study was designed to estab-
lish the incidence of post-CEA restenosis/occlusion in a
series of patients consecutively undergoing primary CEA
followed up according to a strict clinical and ultrasono-
graphic protocol.
METHODS
The local institutional review board approved this
study. Between January 1, 1990, and May 31, 2012, there
were 2007 consecutive primary CEAs performed in 1773
patients at our tertiary referral vascular surgical center. The
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recommendations1 for symptomatic patients and on the
Asymptomatic Carotid Atherosclerosis Study (ACAS)3
for asymptomatic patients. Patients were prospectively
enrolled in the present study. Patients scheduled for
CEA with concomitant coronary artery bypass grafting
or concurrent surgery for associated supra-aortic trunk
lesions and patients needing procedures for recurrent
disease were excluded from the present analysis. The
patients’ demographic and clinical data were recorded
on a standardized form, including potential atheroscle-
rotic risk factors, anatomical and clinical variables, preop-
erative medication, details of surgery, and all perioperative
outcomes. For most patients, the diagnosis of carotid dis-
ease was based on preoperative duplex ultrasound scans
combined with magnetic resonance (MR) angiography,
computed tomography (CT) angiography, or digital sub-
traction angiography in selected patients (ie, those who
had either a pseudo-occlusion on duplex ultrasound or a
stenosis of the carotid intracranial segment detected by
transcranial Doppler sonography). For most of the symp-
tomatic patients and all those without symptoms, the
velocity criteria were taken into account for CEA
decision-making purposes, as explained elsewhere.14 All
patients underwent neurological assessment by the consul-
tant neurologist before surgery, on awakening from the
anesthesia, before discharge from the hospital, and during
the follow-up. All patients with diabetes, hyperlipidemia,
and/or hypoechoic plaques were receiving statin therapy.
Since 2005, all patients with transient ischemic attack
(TIA) were routinely started on clopidogrel before surgery.
Preoperative patient preparation was standardized. Preop-
erative cardiac work-up was tailored to each individual on
the basis of his or her clinical history, electrocardiographic
(ECG) ﬁndings, and symptoms. Patients with evidence of
clinically important coronary artery disease underwent
echocardiography or dipyridamole-thallium stress tests fol-
lowed by coronary arteriography, as indicated.
All surgical procedures were eversion CEAs (eCEAs)
performed by the same surgeon in patients under general
anesthesia and with routine intraoperative electroencepha-
lographic monitoring for a selective use of intraluminal
shunting. The technical details of the eCEA have been
described elsewhere.15 Shunting depended exclusively on
electroencephalographic changes consistent with cerebral
ischemia occurring during carotid cross-clamping, unre-
lated to any bradycardia or arterial hypotension.16 Patients
were administered intravenous unfractionated heparin
(5000 U) before carotid clamping. No completion angio-
scopy or imaging studies were performed.
Patients were usually monitored in the recovery
room for 2 hours until their blood pressure and neuro-
logical status were judged acceptable; they were then
transferred to a nursing unit specialized in vascular care
and monitored for the next 12 to 24 hours after surgery.
All patients with severe headache were observed for
hyperperfusion syndrome, and hypertension was treatedaggressively. Most patients were discharged 36 to 48 hours
after their CEA.
Surveillance protocol. After discharge, visiting nurses
monitored the patients’ blood pressure and neurological
status. All surviving patients systematically underwent
physical and neurological assessment by a consultant
neurologist, and concomitant duplex ultrasound scan per-
formed by two experienced neurosonographers at 1, 6,
and 12 months, then yearly after surgery. All examina-
tions were performed with a high-resolution, color-
coded duplex sonography scanner (the Acuson Sequoia
512 ultrasound system up until 2008, and Philips iU 22
from 2008 onward) with the use of a high-frequency
(5-10 MHz) linear probe. The ultrasound follow-up
schedule was modiﬁed if any progressing or severe
lesions were detected or if patients became symptomatic.
A peak systolic velocity of >130 cm/s with spectral
broadening throughout the systole and an increased peak
diastolic velocity were consistent with a stenosis $50%
diameter reduction, whereas a peak systolic velocity
>240 cm/s was consistent with $70% stenosis. Any
stenosis $70% identiﬁed on duplex ultrasound scanning
was conﬁrmed by CT angiography or MR angiography.
Neurological events were always classiﬁed by the consul-
tant neurologist as TIA, deﬁned as temporary hemi-
spheric symptoms lasting no more than 24 hours, with
complete recovery; amaurosis fugax, a transient monoc-
ular visual loss; minor stroke, a clinical syndrome of
rapidly developing signs or symptoms of focal loss of
cerebral function of vascular origin, lasting more than
24 hours but not leading to any handicap or signiﬁcant
impairment in activities of daily living, rated as <3 on the
modiﬁed Rankin scale17; or major stroke, deﬁned as a
focal neurological deﬁcit lasting >30 days and inducing a
change in lifestyle, assessed as 3 to 5 on the modiﬁed
Rankin scale. Brain imaging (CT or MR imaging) was
performed in all patients presenting a new neurological
deﬁcit after CEA. Cardiac complications were classiﬁed by
a single cardiologist and included (1) myocardial infarc-
tion with a diagnosis on the basis of creatine kinase-MB
levels and ECG ﬁndings; (2) pulmonary edema
conﬁrmed by chest radiography; (3) documented ven-
tricular ﬁbrillation or primary cardiac arrest; and (4) new
congestive heart failure, requiring a pacemaker. A post-
operative ECG was routinely obtained in all patients with
a history of coronary artery disease, congestive heart
failure, or arrhythmia (rhythm other than sinus), and
cardiac isoenzymes were surveyed in all patients who had
new ﬁndings at postoperative ECG. Other complications
and events observed during the follow-up were recorded
in accordance with the guidelines of the Ad Hoc
Committee on Reporting Standards for Cerebrovascular
Disease, Society for Vascular Surgery/North American
Chapter of the International Society of Cardiovascular
Surgery.18
Primary end points were perioperative stroke and death
and late carotid restenosis/occlusion rate.
Table I. Demographics and clinical data
Preoperative characteristics No. (%)
Patients 1773 (100)
CEA procedures 2007 (100)
Mean age 6 SD, years 75.2 6 5.3
<70 558 (31.5)
70-80 912 (51.4)
>80 303 (17.1)
Male sex 1251 (70.6)
Risk factors
Hypertensiona 1053 (59.4)
Smokingb 1223 (68.9)
Diabetes 574 (32.4)
Hyperlipidemiac 803 (45.3)
Cardiac disease 766 (43.2)
CKD 141 (7.9)
Pulmonary disease 285 (16.1)
PAD 977 (55.1)
Qualifying event 1446 (72.1)
Hemispheric stroke 504 (25.1)
TIA 675 (33.6)
Retinal ischemia 267 (13.3)
No symptoms 561 (27.9)
CEA, Carotid endarterectomy; CKD, chronic kidney disease; PAD, pe-
ripheral atherosclerotic disease; SD, standard deviation; TIA, transient
ischemic attack.
aArterial pressure >140/90 mm Hg or blood pressure treated with
medication.
bCurrent use or cessation within the past 5 years.
cSerum concentration of cholesterol >6.5 mmol/L or triglycerides
>2.0 mmol/L.
Table II. Degree of carotid lesions, concomitant
medication, and intraoperative variables
No. (%)
Degree of ipsilateral stenosis
<50% 69 (3.4)
50%-59% 23 (1.1)
60%-69% 148 (7.3)
70%-79% 857 (42.7)
80%-89% 665 (33.1)
90%-99% 245 (12.2)
Contralateral carotid disease
<60% 1292 (72.9)
$60% 194 (10.9)
Occlusion 287 (16.2)
Concomitant medication
Antiplatelet treatment 1552 (87.5)
Clopidogrel 478 (26.8)
Clopidogrel plus aspirin 222 (12.5)
Aspirin 526 (29.7)
Ticlopidine 255 (14.4)
Dipyridamole 71 (4.0)
Anticoagulant (warfarin) 123 (6.9)
Lipid-lowering drug 918 (51.8)
Intraoperative variables
Left side of operation 1107 (55.1)
Shunt placement 318 (15.8)
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formed with the SSPS statistical software (SPSS version
12.0.1; SPSS Inc, Chicago, Ill). Patients’ demographic data
are given as medians, means, and ranges and baseline clinical
and diagnostic ﬁndings in terms of incidence rates. Stroke-
free survival and survival rates were calculated by means of
the Kaplan-Meier method and are reported as “life-table”
analyses. Signiﬁcance was assumed at P < .05. Several data
items were analyzed vis-à-vis surgical procedures rather than
patients because each perioperative outcome was correlated
with the surgical procedure and because patients who un-
derwent bilateral CEAs were exposed to twice the risk of
stroke, death, or other complications.
RESULTS
Descriptive analysis. Patients’ demographic details,
risk factors, and indications for CEA are summarized in
Table I. Among the 1773 patients who underwent 2007
CEAs (234 were staged bilateral CEA procedures), there
were 522 women (29.4%) and 1251 men (70.6%), with a
mean age of 75.2 years (range, 31 to 96 years). More than
two in three of the lesions (72.1%; 1446 of 2007) were
symptomatic, with a 25% rate of preoperative strokes. The
interval from presentation to operation for TIA/minor
stroke patients was <1 month, whereas asymptomatic cases
or patients with major stroke were treated within 6 months
from diagnosis/event, respectively. No adverse ischemic
events occurred during the waiting period. It is noteworthy
that the ipsilateral carotid artery had a stenosis between
75% and 99% in more than half of the cases, whereas the
contralateral carotid artery was occluded in 287 cases
(16.2%). More than 90% of patients (1675 of 1773) were
receiving antiplatelet or anticoagulant treatment at pre-
sentation, that is, 478 patients (26.8%) were taking clopi-
dogrel (75 mg/d), 526 (29.7%) aspirin (100 mg/d), 255
(14.4%) ticlopidine (500 mg/d), 71 (4.0%) dipyridamole
(400 mg/d), 222 (12.3%) clopidogrel plus aspirin, and 123
(6.9%) warfarin. Statin medication was being used by 918
patients (51.8%; Table II).
Perioperative (30-day) stroke and mortality rates.
Overall, there were eight (0.39%) perioperative strokes (ﬁve
major and three minor) and no deaths (Table III). In all
eight cases, the stroke occurred in symptomatic patients
within the ﬁrst 24 hours of surgery, while they were still in
the recovery room, and prompt duplex ultrasound scan
showed that the endarterectomized artery was patent. Four
major strokes occurred in patients (one of themwas shunted)
who had a mildly diseased contralateral carotid artery and,
judging from the cerebral CT scans, they produced a cortical
infarction in the territory of the middle cerebral artery;
because they could not be caused by technical errors, we
assumed that they were probably embolic (from the aortic
arch or the heart). The other major stroke was ipsilateral to
an occluded contralateral carotid artery. All minor strokes
were most likely hemodynamic in nature because they were
identiﬁed as border zone infarcts on CT imaging: two of
them developed in the hemisphere contralateral to the
revascularized carotid artery and ipsilateral to an occludedinternal carotid artery. Among the 504 patients (25.1%)
with a preoperative stroke, we observed three perioperative
strokes, with no clear correlation between preoperative
cerebral imaging and outcome (P ¼ .42).
Table III. Perioperative (30-day) outcomes
Outcomes
2007 CEAs
(1773 patients), No. (%)
Stroke 8 (0.39)
Major 5 (0.24)
Ipsilateral 4
Shunting 1
No shunting 3
CCO 0
Contralateral 1
Shunting 0
No shunting 1
Carotid occlusion 1
Minor 3 (0.14)
Ipsilateral 1
Shunting 0
No shunting 1
CCO 0
Contralateral 2
Shunting 0
No shunting 2
Carotid occlusion 2
TIA 40 (1.99)
Ipsilateral 23 (1.14)
Contralateral 17 (0.84)
Stroke plus TIA 48 (2.39)
Death 0
Cerebral hemorrhage 0
Hyperperfusion syndrome 0
Nonfatal myocardial infarction 1 (0.04)
Nerve injury 91 (4.53)
Cervical re-exploration for bleeding 86 (4.28)
CCO, Contralateral carotid occlusion; CEA, carotid endarterectomy; TIA,
transient ischemic attack.
Table IV. Long-term results
Outcomes 1905 CEAs (1680 patients), No. (%)
Stroke 9 (0.47)
Ipsilateral 4 (0.21)
Contralateral 5 (0.26)
Death 159 (9.46)
Stroke-related 2 (0.10)
Restenoses 9 (0.47)
50%-69% 6 (0.31)
$70% 3 (0.15)
Carotid occlusion 1 (0.05)
All restenoses plus occlusions 10 (0.52)
CEA, Carotid endarterectomy.
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(1.99%) perioperative TIAs observed in all, 17 (0.84%)
occurred in the middle cerebral artery territory contralat-
eral to the operated side. In all cases, duplex ultrasound
scanning immediately after the onset of neurological signs
showed that the revascularized carotid artery was patent,
and cerebral CT/MR images were negative for any new
ischemic events (Table III).
Other complications. Overall, there was only one
perioperative cardiac complication (0.04%) in a male
patient, which was managed conservatively. None of the
patients had any cerebral hemorrhage or hyperperfusion
syndrome. Overall, postoperative arterial hypertension
needing medication in the recovery room was recorded
in 271 eCEA procedures (13.5%), and, to reduce the risk
of hyperperfusion syndrome, these patients were treated
by means of an intravenous infusion of the medication
(mainly urapidil). There were 91 nerve injuries (4.5%) alto-
gether, 62 (3.1%) involving the cranial nerves and 29
(1.4%) the cervical nerves. Other surgical morbidities
included 86 (4.28%) neck hematomas requiring surgical
evacuation but causing no further complications
(Table III). This prompted a change in practice during
the study period: intraoperative heparinization was never
reversed with protamine up until 2009, but from January
2010 onward, all patients had partial (half-dose) heparinreversal. Our decision to arbitrarily use a partial heparin
reversal was based on the amount of residual heparin
thought to be still in circulation at the moment of
neutralization, given its relatively short half-life and the
limited carotid cross-clamping time during eCEA, which
was averaged <25 minutes in our hands. This meant that
CEA was always performed with the certainty of a com-
plete systemic anticoagulation, but its effects were not
prolonged after declamping. After this change was intro-
duced, there were no further postoperative neck hema-
tomas needing re-exploration.
Long-term results. Among the 1773 patients alive
30 days after their CEA, 93 (5.2%; 102 CEAs) were lost
to follow-up. A complete follow-up (median, 11.2 years;
mean, 12.9 6 0.8 years; range, 1-20 years) was thus ob-
tained for 1680 patients (94.8%) and an overall 1905 CEA
procedures (94.9%).
Overall, only one carotid occlusion was detected
(0.05%): this occurred in a male patient without symptoms
within the ﬁrst postoperative year and involved a carotid
artery that had not been shunted and that had been patent
at the ﬁrst two duplex ultrasound scans (Table IV).
Altogether, nine restenoses (0.47%) were $50%,
involving vessels that had not been shunted and occurring
without symptoms, mainly within 24 months of surgery;
only three of them (0.15%) were $70% (Table IV). The
ﬁrst of these three $70% restenoses remained stable at sub-
sequent duplex ultrasound scans and was treated conserva-
tively, whereas the other two rapidly progressed, becoming
severe enough to require a second CEA and a CAS proce-
dure, respectively, 19 and 33 months after the ﬁrst revascu-
larization. Kaplan-Meier analysis showed that the rates of
freedom from restenosis/occlusion at 1, 5, 10, and 12 years
were 99.9 6 0.1%, 99.3 6 0.2%, 99.3 6 0.2%, and 99.3 6
0.2%, respectively (Fig).
Overall, there were nine late strokes (0.47%), none of
which occurred in patients with recurrent stenosis. Three
were cardioembolic and four were lacunar (two contralat-
eral to the operated side) whereas two (ipsilateral to the
operated side and contralateral to a carotid occlusion)
were probably hemodynamic in nature, judging from the
CT images (Table IV). Kaplan-Meier analysis showed
that the rates of freedom from stroke at 1, 5, 10, and
Fig. Kaplan-Meier analysis curves show the freedom from >50%
restenosis/occlusion (dotted line), late stroke risk (line), and late
survival (bulleted line). Percentages on the right represent the rates
at 12 years. The standard error is <10% at each time point for all
curves, ranging from 0% to 0.2% for restenosis/occlusion, from 0%
to 1.7% for stroke risk, and from 0% to 8.4% for late survival. Raw
numbers of eversion carotid endarterectomy (eCEA) procedures
(restenosis/occlusion and stroke) and patients (survival) at risk
analyzed at each time point are provided below the ﬁgure.
JOURNAL OF VASCULAR SURGERY
1278 Ballotta et al May 201412 years were 99.46 0.2%, 98.66 0.4%, 97.66 1.7%, and
97.6 6 1.7%, respectively (Fig).
There were 159 late deaths (9.4%) in the series as a
whole. The cause was primarily cardiac-related (n ¼ 88;
55.3%), whereas two deaths were stroke-related, one
involving a female patient with atrial ﬁbrillation of recent
onset, and the other contralateral to the revascularized
side and ipsilateral to a carotid occlusion. The survival rates
at 1, 5, 10, and 12 years were 99.6 6 0.2%, 90.2 6 0.9%,
67.3 6 7.7%, and 55.2 6 8.4%, respectively (Fig).
DISCUSSION
Large RCTs have shown that CEA is superior to the
best medical therapy in the prevention of stroke in symp-
tomatic patients with severe carotid stenosis1,2 and in
selected cases of asymptomatic carotid disease.3,4 For
CEA to be meaningful, however, the long-term beneﬁt
(in terms of stroke prevention) must balance the perioper-
ative risk (stroke and death).5 Although the perioperative
stroke and mortality rates after CEA reported in the
RCTs are still considered acceptable, they are 15 to 20 years
old, and the literature has demonstrated that these rates
have dropped drastically over time, thus setting a high stan-
dard of care for comparison with evolving stenting proce-
dures. As well as the often-emphasized perioperative
results, the durability of CEA is intuitively important too,
with a view to avoiding the risk of secondary procedures
being needed for any signiﬁcant progression of restenoses,
even without counting the fact that they can trigger
adverse clinical events such as TIA and stroke.
The results of the present study correlate well with
other large, contemporary surgical series, going to show
that eCEA has an extremely low perioperative risk and isan excellent treatment for selected symptomatic and
asymptomatic carotid lesions (Table V).19-32 Because late
carotid occlusions and recurrent stenoses are the real indi-
cators of CEA durability, our combined occlusion and
>70% restenosis rate of 0.21% over a mean follow-up of
12.9 years clearly demonstrates that eCEA is a durable
procedure, against which other interventional treatment
options should be matched.
Because the occurrence of post-CEA restenosis is
mainly related to how the arteriotomy is closed, a number
of technical variations have been introduced to minimize its
incidence.
Two CEA techniques are currently used: conventional
CEA with patching and eCEA, because CEA with primary
closure is not to be recommended and has been virtually
abandoned because of inferior early outcomes and a high
incidence of late restenosis.33 eCEA involves the oblique
transection of the internal carotid artery from the common
carotid artery at the bulb, with an incision almost longitu-
dinal, making a long hole on the lateral wall of the com-
mon carotid artery. The adventitia of the internal carotid
artery is then everted over its atherosclerotic core to the
end of the plaque, thus enabling to close and direct visual-
ization of the end point for its entire circumference, simpli-
fying the careful debridement of all circular ﬁbers and the
complete removal of loose fragments, with no need for
end point tacking sutures. After completion of the internal
carotid artery endarterectomy, the eversion is reduced. The
arteriotomy can be extended into the common carotid ar-
tery to facilitate the removal of the common and external
carotid arteries’ plaque, so that the suture line is in
the adventitia and nowhere in the plaque area. The
reanastomosis of the internal carotid artery with the com-
mon carotid artery allows widening of both lumens, preser-
ving the original carotid conﬁguration, with the internal
and common carotid arteries ultimately patching each
other. In a recent Cochrane Collaboration Systematic
Review comparing the above two CEA methods, the
authors concluded that there is currently no evidence of
the superiority of one over the other in terms of perioper-
ative stroke.34 The optimal surgical technique for CEA
therefore has yet to be ascertained, and the choice of one
or other continues to depend on the personal experience
and preferences of the surgeons involved, although eCEA
has commonly been identiﬁed as an independent factor
contributing to better long-term results.19,21,29,35
Since 1990,when eCEAwas ﬁrst introduced at our insti-
tution, this technique has gradually replaced conventional
CEA with routine patching in our daily surgical practice as
the treatment of choice for patients with carotid occlusive
disease. We have used exclusively eCEA to treat all primary
carotid lesions since 1998. Although the numerous advan-
tages of eCEA include short clamping and operating
times, no need for prosthetic material, an easier correction
of concomitant redundant carotid artery, and a lower inci-
dence of restenosis, the few concerns raised regarding this
method relate to the potential incomplete visualization of
the distal endarterectomy end point and the reported
Table V. Early and late outcomes in large series adopting preferably conventional CEA with patching and/or eCEA
AuthorRef Method of closure (%)
Mean follow-up,
years CEA/patients Symptoms, %
30-day
death/stroke, % RS, %
Late
CO þRS, %
Shah19 Patching (3) 1.5 474/410 44 4.5 >60 1
Eversion (82) 1.5 2249/1855 34 2.3 0.3
Archie20 Patching (99.6) 4.6 1289 62 2.1 >50 2.1
Primary (0.4) 4.6 51 0
Cao21 Patching (19) 2.7 256 N/A N/A >50 1.5
Primary (31) 2.7 419 60 1.3 7.9
Eversion (50) 2.7 678 57 1.3 2.8
Scavee22 Patching (100) 4.1 600 46 0.9 >50 5.8
Trisal23 Patching (62) N/A 1648 N/A N/A >70 3.8
Primary (38) 5.8
LaMuraglia24 Selective patching 6.1 2127/1853 36 1.4 >70 9.8
Crawford25 Patching (53) 5.5 155/155 30 1.1 >70 5.2
Eversion (47) 3.5 135/135 31 0 5.9
Black26 Eversion (100) 8.86 534/485 44 3.8 >60 4.1
Goodney27 Patching (88) 1.1 2611 52 Overall, 1.2 >80 2
Eversion (12) 1.1 370 6
Van Lammeren28 Selective patching 1 1203/1203 85 N/A >50 14.7
Radak29 Eversion (100) N/A 9897/9181 98 1.9 >50 4.3
Demirel30 Patching (40) 2 310 100 3 >70 3.2
Eversion (60) 2 206 100 9 2.4
Babu31 Patching (100) 15.8 1492/1335 60 0.9 >70 0.4
Hertzer32 Patching (66) 5-10 1301/1129 32 Overall, 2.7 >60 10.3
Primary (34) 5-10 658/559 42 30
Present series Eversion (100) 15.9 2007/1773 72.1 0.39 >50 0.52
CEA, Carotid endarterectomy; CO, carotid occlusion; eCEA, eversion CEA; N/A, not available; RS, recurrent stenosis.
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CEA procedures considered in this series were aborted or
incomplete, however, and none of the patients were refused
eCEA for technical issues arising during surgery.
The reported rates of recurrent stenosis after CEA vary,
but any comparison of the results between the different
series is bound to be methodologically ﬂawed, given the
differences in its deﬁnition, the length of patient follow-
up, and the technique used to perform the CEA. In a
recently-published series of 1492 CEAs with patching per-
formed in 1335 patients followed up for a mean 15.8 years,
the rate of >70% recurrence was 0.4% (much the same as
ours).31 Similarly, an analysis on 2723 CEA procedures
(2249 eCEAs and 474 CEAs with patching, performed
in 1855 and 410 patients, respectively) identiﬁed an inci-
dence of >60% restenosis of 0.3% for eCEAs and 1% for
conventional CEAs over a mean follow-up of 1.5 years.19
Further studies, including an RCT comparing CEA with
patching and eCEA,21 and other large single-center series
($500 CEA procedures) adopting only one type of surgi-
cal technique22,24,26,28,29,31 or combinations of conven-
tional CEA and eCEA,19,25,27,30 reported recurrence rates
ranging from 1.5% to 14.7% for conventional CEA and
from 2.4% to 6% for eCEA, with an overall mean follow-
up ranging from 1.1 to 8.9 years (Table V).
In recent years, CAS has emerged worldwide as a
potential alternative to CEA for the treatment of carotid
disease. Our indications for CAS are restricted to a smallsubset of patients, such as individuals with severe or symp-
tomatic recurrent stenosis after CEA or with radiation-
induced stenosis. Although data from centers with
high-volume experience have demonstrated the technical
feasibility and safety of CAS, a recent meta-analysis of
pooled individual patient data from three RCTs comparing
CAS with CEA (mainly in symptomatic patients),6 and the
latest randomized evidence from a large RCT comparing
CAS with CEA in both symptomatic and asymptomatic
patients7 clearly indicate that more periprocedural strokes
and deaths occur with CAS than with CEA. Currently
emerging long-term results demonstrate the durability of
CAS, but there are limited data to support the claim
of the noninferiority of CAS to CEA. Only a few
nonrandomized studies have focused on the incidence of
restenosis after CAS, through the use of very different
follow-up protocols. Although several thousand CAS pro-
cedures have been described in the literature, the real inci-
dence of in-stent restenosis remains unknown because
different studies report quite different rates, ranging
from <5%36 to >21%.37 A secondary analysis of the
Carotid Revascularization Endarterectomy vs Stenting
Trial (CREST)38da large RCT comparing outcomes of
CAS vs CEA in 2502 patients enrolled at 117 centers in
the United States and Canadadreported a >70% restenosis
rate of 6% after CAS at 2 years, which was comparable with
the 6.2% restenosis rate after CEA. In previous RCTs on
CAS vs CEA, the incidence of restenosis after CAS varied
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1280 Ballotta et al May 2014from 3% at 3 years (in a sample of 143 patients) to 11.1% at
2 years (among 541 patients) and to 16.6% at 5 years
(considering 50 patients).38
As in other institutional series demonstrating that
restenosis is rarely responsible for neurological symp-
toms,10,31 no late adverse ischemic events occurred in
our patients with post-CEA restenosis; considering the
relatively short interval before its onset after surgery, this
might be related to the nonembolic nature of the new
carotid lesion (intimal hyperplasia). On the other hand,
other studies have found that restenosis increases the risk
of ipsilateral stroke. A recently-published single-center
series on 361 patients who had CEA between 1970 and
2002 showed that recurrent stenosis in the ipsilateral
carotid artery occurred at a rate of 5.2% at 5 years and
37% at 20 years and found that the likelihood of further
ipsilateral adverse ischemic events in a substrate of recur-
rence was 10% after 5 years and 50% after 20 years.39
More than 88% of the conventional CEA procedures in
this series were completed with primary closure, however.
Similarly, post hoc analysis of the CREST proved that indi-
viduals who had development of restenosis/occlusion
within 2 years were at greater risk of ipsilateral stroke after
the periprocedural period and up until the end of their
follow-up than those who did not have development of
restenosis/occlusion within 2 years.38 The investigators
admitted, however, that they were unable to state whether
restenosis developed before or after stroke.
Although a late TIA or stroke occurring on the same
side as a CEA is not necessarily correlated with carotid dis-
ease, our 0.39% risk of ipsilateral stroke goes to show that
the eCEA procedure offers a good protection against the
risk of late cerebral ischemia.
Limitations of the study. Some limitations of our
study warrant consideration. First, all our nonrandomized,
observational data were collected prospectively but
analyzed retrospectively. Second, the study represents a sin-
gle surgeon’s experience with eCEA at a single institution,
and, although this ensures that the surgical technique was
the same for every operation, it does not mean that the re-
sults are reproducible; to make these ﬁndings more gener-
alizable, a wider, more representative sample of surgeons
and institutions must be considered. Third, this is a case se-
ries, not a comparative study of recurrent stenosis,
exploring the differences between eCEA and conventional
CEA with patching or CAS. Our analysis was undertaken
to demonstrate that eCEA affords perioperative mortality
and morbidity rates and a durability that makes it worthy
of consideration when advising patients on how best to
manage their carotid occlusive disease.
CONCLUSIONS
The results of this observational study show that eCEA
can be performed in symptomatic and asymptomatic
patients with an extremely low perioperative stroke/death
risk and a negligible incidence of late restenosis/occlusion,
affording good long-term protection against the risk of
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